Secondaries Announced 10.17.17

IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis.

If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today!

Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or opening trade) time period.

Company: Akari Therapeutics
Symbol: AKTX
Price: Last Trade $6.40
Trade Date: 10/18
Shares: 3.3 million ($17.4m cash raise)
Re-Offer Range: Subscription Needed
Underwriter(s) : Cantor Fitzgerald, William Blair, Canaccord Genuity
Description: Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, in particular those where the complement system or leukotrienes or both complement and leukotrienes together play a primary role in disease progression.
Rating = Subscription Needed

Company: RADCOM, Ltd.
Symbol: RDCM
Price: Last Trade $20.20
Trade Date: 10/18
Shares: 1.4 million ($28m cash raise)
Re-Offer Range: Subscription Needed
Underwriter(s) : William Blair, Needham & Co.
Description: RADCOM, is a provider of end-to-end quality monitoring and service assurance solutions for telecommunications carriers founded in 1991.
Rating =Subscription Needed